Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-02-11 4:26 pm Purchase |
2021-12-31 | 13G | Harpoon Therapeutics, Inc. HARP |
ORBIMED ADVISORS LLC | 166,790 5.100% |
64,720 (+63.41%) |
Filing History |
| 2022-02-11 4:23 pm Sale |
2021-12-31 | 13G | Gracell Biotechnologies Inc. GRCL |
ORBIMED ADVISORS LLC | 5,970,672 8.900% |
-23,882,692 (-80.00%) |
Filing History |
| 2022-02-11 4:22 pm Sale |
2021-12-31 | 13G | Forte Biosciences, Inc. FBRX |
ORBIMED ADVISORS LLC | 0 0.000% |
-25,431 (Position Closed) |
Filing History |
| 2022-02-11 4:21 pm Sale |
2021-12-31 | 13G | Standard BioTools Inc. LAB |
ORBIMED ADVISORS LLC | 3,416,871 4.460% |
-82,375 (-2.35%) |
Filing History |
| 2022-02-11 4:19 pm Purchase |
2021-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
ORBIMED ADVISORS LLC | 3,196,876 6.700% |
443,309 (+16.10%) |
Filing History |
| 2022-02-11 4:18 pm Purchase |
2021-12-31 | 13G | Catalyst Biosciences, Inc. CBIO |
ORBIMED ADVISORS LLC | 342,423 4.300% |
342,423 (New Position) |
Filing History |
| 2022-02-11 4:14 pm Purchase |
2021-12-31 | 13G | Applied Therapeutics, Inc. APLT |
ORBIMED ADVISORS LLC | 2,100,681 8.000% |
433,856 (+26.03%) |
Filing History |
| 2022-02-11 4:12 pm Sale |
2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
ORBIMED ADVISORS LLC | 158,245 7.900% |
-42,376 (-21.12%) |
Filing History |
| 2022-02-11 4:10 pm Sale |
2021-12-31 | 13G | Adverum Biotechnologies, Inc. ADVM |
ORBIMED ADVISORS LLC | 0 0.000% |
-484,525 (Position Closed) |
Filing History |
| 2022-02-02 4:33 pm Unchanged |
2022-01-31 | 13D | Sierra Oncology, Inc. SRRA |
ORBIMED ADVISORS LLC | 3,044,753 15.300% |
0 (Unchanged) |
Filing History |
| 2021-12-17 5:08 pm Purchase |
2021-12-16 | 13D | Janux Therapeutics, Inc. JANX |
ORBIMED ADVISORS LLC | 2,649,464 6.400% |
2,649,464 (New Position) |
Filing History |
| 2021-12-14 5:29 pm Purchase |
2021-12-10 | 13D | RESTORBIO INC TORC |
ORBIMED ADVISORS LLC | 6,147,599 15.700% |
214,285 (+3.61%) |
Filing History |
| 2021-12-06 4:25 pm Sale |
2021-12-02 | 13G | CTI BioPharma Corp. CTIC |
ORBIMED ADVISORS LLC | 4,024,821 4.000% |
-5,495,179 (-57.72%) |
Filing History |
| 2021-11-18 5:10 pm Unchanged |
2021-11-15 | 13D | Theseus Pharmaceuticals, Inc. THRX |
ORBIMED ADVISORS LLC | 16,838,668 43.500% |
0 (Unchanged) |
Filing History |
| 2021-11-18 4:56 pm Sale |
2021-11-12 | 13D | Acutus Medical, Inc. AFIB |
ORBIMED ADVISORS LLC | 2,648,386 9.500% |
-4,233,567 (-61.52%) |
Filing History |
| 2021-11-12 5:05 pm Purchase |
2021-11-10 | 13D | Alpine Immune Sciences, Inc. ALPN |
ORBIMED ADVISORS LLC | 4,226,843 14.400% |
1,010,637 (+31.42%) |
Filing History |
| 2021-11-09 5:30 pm Purchase |
2021-11-04 | 13D | Compass Therapeutics, Inc. CMPX |
ORBIMED ADVISORS LLC | 18,071,547 18.400% |
5,357,143 (+42.13%) |
Filing History |
| 2021-11-05 4:26 pm Purchase |
2021-11-05 | 13D | Sierra Oncology, Inc. SRRA |
ORBIMED ADVISORS LLC | 3,044,753 18.100% |
3,033,090 (+26006.64%) |
Filing History |
| 2021-11-03 3:03 pm Unchanged |
2021-11-02 | 13D | Corvus Pharmaceuticals, Inc. CRVS |
ORBIMED ADVISORS LLC | 6,943,654 14.900% |
0 (Unchanged) |
Filing History |
| 2021-11-02 5:01 pm Sale |
2021-11-01 | 13D | Repare Therapeutics Inc. RPTX |
ORBIMED ADVISORS LLC | 3,177,041 7.700% |
-99,284 (-3.03%) |
Filing History |